Trial watch: antibody-drug conjugates in cancer therapy

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antibody-drug conjugates (ADCs) integrate monoclonal antibodies with cytotoxic payloads for targeted cancer therapy.
• ADCs have become a validated approach in precision oncology, with numerous FDA approvals and ongoing clinical trials.

Purpose of the Study:

• To provide a comprehensive overview of ADCs from preclinical stages to clinical applications.
• To summarize key design principles of successful ADCs and their impact on efficacy and toxicity.
• To discuss clinical trial results and approved agents, outlining future directions for ADC development.

Main Methods:

• Review of preclinical and clinical data on approved and investigational ADCs.
• Analysis of ADC design elements: epitope targeting, linker chemistry, payload, and drug-to-antibody ratio.
• Evaluation of factors influencing ADC pharmacokinetics, intracellular trafficking, bystander effect, and toxicity.

Main Results:

• ADCs have demonstrated significant clinical benefits in both hematologic malignancies and solid tumors.
• Multiple ADCs are approved by the FDA, with hundreds more in clinical development.
• Key design features significantly influence ADC performance and therapeutic outcomes.

Conclusions:

• ADCs represent a powerful therapeutic modality in modern oncology.
• Understanding ADC design principles is crucial for optimizing efficacy and minimizing toxicity.
• Continued research and clinical trials are essential to further advance ADC-based cancer treatments.